Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

HR Summit, one of the most important events dedicated to the human resources industry in Transylvania, will take place under ...

The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, Ahmad ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Moreover, they may have significant fluctuations and high peak-to-trough ratios, requiring daily subcutaneous injections. Ascendis Pharma’s (ASND) Palopegteriparatide is a once-daily PTH replacement ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

December S&P 500 E-Mini futures (ESZ24) are up +0.14%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.01% this morning as investors awaited crucial U.S. producer inflation data, remarks from ...

GET MORE AI-GENERATED SIGNALS: November 10, 2024, 17:44 pm ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $209, which is approximately 33.55% ...

On Monday, Goldman Sachs raised the price target for Ascendis Pharma (NASDAQ:ASND) to $195 from $170, while keeping a Buy rating on the stock. This adjustment follows the U.S. Food ...